Teplizumab can allow patients to live “normal lives” without the need for insulin injections
Notifications can be managed in browser preferences.
Next article
Teplizumab can allow patients to live “normal lives” without the need for insulin injections
I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
A groundbreaking new drug that slows down the development of type 1 diabetes has been licensed for use in the UK.
Teplizumab licensed for use by adults and older children in ‘breakthrough moment’
The new technology, known as a hybrid closed loop system, will help reduce the risk of stillbirth and miscarriage
Drug can lead to blood pressure fall large enough to cut cardiovascular risk, study finds
A trial cut hospital admissions by 72 per cent
New study raises urgent questions about how doctors treat diabetes
Early trials have shown a massive reduction in seizures among young people with Dravet syndrome
